...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05).
【24h】

Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05).

机译:放射疗法治疗骨转移引起的神经性疼痛的随机对照试验:8 Gy合1与20 Gy合5比例放射治疗(Trans-Tasman放射肿瘤学小组,TROG 96.05)。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: Despite numerous randomized trials investigating radiotherapy (RT) fractionation schedules for painful bone metastases, there are very few data on RT for bone metastases causing pain with a neuropathic component. The Trans-Tasman Radiation Oncology Group undertook a randomized trial comparing the efficacy of a single 8 Gy (8/1) with 20 Gy in 5 fractions (20/5) for this type of pain. MATERIALS AND METHODS: Eligible patients had radiological evidence of bone metastases from a known malignancy with no change in systemic therapy within 6 weeks before or anticipated within 4 weeks after RT, no other metastases along the distribution of the neuropathic pain and no clinical or radiological evidence of cord/cauda equina compression. All patients gave written informed consent. Primary endpoints were pain response within 2 months of commencement of RT and time to treatment failure (TTF). The hypothesis was that 8/1 is at least as effective as 20/5 and the planned sample size was 270 patients. RESULTS: Between February 1996 and December 2002, 272 patients were randomized (8/1:20/5=137:135) from 15 centres (Australia 11, New Zealand 3, UK 1). The commonest primary cancers were lung (31%), prostate (29%) and breast (8%); index sites were spine (89%), rib (9%), other (2%); 72% of patients were males and the median age was 67 (range 29-89). The median overall survival (95% CI) for all randomized patients was 4.8 mo (4.2-5.7 mo). The intention-to-treat overall response rates (95% CI) for 8/1 vs 20/5 were 53% (45-62%) vs 61% (53-70%), P=0.18. Corresponding figures for complete response were 26% (18-34%) vs 27% (19-35%), P=0.89. The estimated median TTFs (95% CI) were 2.4 mo (2.0-3.3 mo) vs 3.7 mo (3.1-5.9 mo) respectively. The hazard ratio (95% CI) for the comparison of TTF curves was 1.35 (0.99-1.85), log-rank P=0.056. There were no statistically significant differences in the rates of re-treatment, cord compression or pathological fracture by arm. CONCLUSIONS: 8/1 was not shown to be as effective as 20/5, nor was it statistically significantly worse. Outcomes were generally poorer for 8/1, although the quantitative differences were relatively small.
机译:背景与目的:尽管有大量的随机试验研究了疼痛性骨转移的放疗(RT)分级方案,但有关引起神经病性疼痛的骨转移的RT数据却很少。 Trans-Tasman放射肿瘤学小组进行了一项随机试验,比较了单个8 Gy(8/1)和20 Gy在5个分数(20/5)中对此类疼痛的疗效。材料和方法:符合条件的患者具有放射学证据,即已知恶性肿瘤的骨转移,在放疗前6周内或放疗后4周内未见全身治疗改变,沿神经性疼痛的分布无其他转移,且无临床或放射学证据绳/马尾马压缩。所有患者均签署知情同意书。主要终点是RT开始后2个月内的疼痛反应和治疗失败时间(TTF)。假设8/1至少与20/5一样有效,计划的样本量为270名患者。结果:1996年2月至2002年12月,从15个中心(澳大利亚11,新西兰3,英国1)中随机抽取了272例患者(8/1:20/5 = 137:135)。最常见的原发癌是肺癌(31%),前列腺癌(29%)和乳腺癌(8%);指标部位为脊柱(89%),肋骨(9%),其他(2%); 72%的患者为男性,中位年龄为67岁(范围29-89)。所有随机分组患者的中位总生存期(95%CI)为4.8 mo(4.2-5.7 mo)。 8/1对20/5的意向治疗总体缓解率(95%CI)为53%(45-62%)对61%(53-70%),P = 0.18。完全缓解的相应数字是26%(18-34%)对27%(19-35%),P = 0.89。估计的TTF中位数(95%CI)分别为2.4 mo(2.0-3.3 mo)和3.7 mo(3.1-5.9 mo)。比较TTF曲线的危险比(95%CI)为1.35(0.99-1.85),对数秩P = 0.056。手臂再治疗,脐带受压或病理性骨折的发生率无统计学差异。结论:8/1没有显示出与20/5一样有效,统计上也没有明显恶化。尽管数量差异相对较小,但8/1的结果通常较差。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号